| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | once-weekly MC4R selective peptide agonist hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome | IND | — | Subscribe to access the data. | Peptides | Rare Diseases | |
IND Submission example | once-weekly MC4R selective peptide agonist hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome | IND | — | Subscribe to access the data. | Peptides | Rare Diseases | |
IND Submission example | once-weekly MC4R selective peptide agonist hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome | IND | — | Subscribe to access the data. | Peptides | Rare Diseases |
Recent Updates
Recently added Catalysts
Palatin Technologies, Inc.$10
-0.49 (-4.67%)
C 47Pipeline Score Fair Value Pharma · Clinical
Market Cap
26.47 M
EPS
-0.81
P/E Ratio
-
Value Trade
150.22 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
3.92 M
R&D Expenses
3.52 M
Total Assets
13.23 M
Total Liabilities
2.63 M
Equity
10.59 M
D/E Ratio
12,345
-0.82 %
Week
-32.81 %
1 Month
-29.8 %
3 Month
1.75 %
6 Month
-97.98 %
5 Year
-100 %
All Time
Cash Data
Cash Position
10.16 M
Monthly Burn
527.00 K
Runway
17.6 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
14.55 K
52 Week Range
5 - 975.25
% held by Insiders
9.1 %
% held by Institutions
55.09 %
Enterprise Value
16.60 M
Total Shares
1.78 M
Short %
11.16 %
Float Shares
1.64 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Palatin Technologies, Inc.
807Total events
5Upcoming
195Tier-1 (high impact)
2007 – 2026Coverage
Upcoming catalysts 5
Event history 802
Q3 2026
◆Trial InitiationTrial
Long-acting peptide MC4R agonist expected to initiate clinical development in second half of 2026
obesitysource ↗
Q3 2026
◆Topline ReadoutPL-9643Clinical Data
Topline data for MELODY-2 expected in second half of 2026
dry eye diseasesource ↗
May 18, 2026
Q2 2026
Q2 2026
Q2 2026
●Trial InitiationTrial
Initiation of Phase 1 SAD/MAD trial for next-generation peptide MC4R agonist
obesitysource ↗
Feb 17, 2026
Q1 2026
●IND SubmissionPL7737IND
PL7737 on track to enter clinical studies in first half of 2026
obesitysource ↗
Drug Pipeline Intelligence
C47
Pipeline Score $73M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored2.7x
rNPV / MCap Top 70%
Micro Cap (rank 274 of 911)
Percentile RankPalatin Technologies, Inc. carries a moderate pipeline score (47/100), with $3.5B risk-adjusted pipeline value, led by Bremelanotide in Kidney Disease (Phase 2), across $141B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bremelanotide Small molecule | Hypoactive Sexual Desire Disorder | Phase 3 | NCT02333071 | 50% | $3.2B | COMPLETED | 1,437 | - | - | Jun 30, 2017 | - | Apr 9, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PL9643 | dry eye disease | Phase 3 | 2025-04-29 | 6 of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05); Statistically significant symptom resolution by week 2; Continued improvement through week 12 with no plateau Read More | Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease Read More | |
PL9643 | dry eye disease | Phase 3 | 2025-04-29 | 6 of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05); Statistically significant symptom resolution by week 2; Continued improvement through week 12 with no plateau Read More | Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease Read More | |
PL9643 | dry eye disease | Phase 3 | 2025-04-29 | 6 of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05); Statistically significant symptom resolution by week 2; Continued improvement through week 12 with no plateau Read More | Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PTN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PTN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PTN▲ +5.8%on this news
Palatin to Begin Trading on Nasdaq Stock Exchange Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting ...
Palatin Technologies, Inc. has announced its common stock will be listed on the Nasdaq Capital Market, transitioning from the NYSE American. Trading under the symbol 'PTN' will commence on May 29, 2026. The CEO expressed optimism about increased visibility and liquidity for the stock. The company continues to develop MC4R-based obesity treatments, with significant milestones expected in the coming years.
Read more →PTN▲ +5.8%on this news
Palatin to Begin Trading on Nasdaq Stock Exchange PRINCETON, NJ
Palatin Technologies, Inc. has announced its common stock will transition from the NYSE American to the Nasdaq Capital Market on May 29, 2026. The company expects this move to enhance visibility and trading liquidity, as well as provide greater exposure to institutional investors. Palatin is focused on developing novel therapeutics targeting the melanocortin receptor system, particularly for rare obesity disorders. Their innovative programs include injectable and oral MC4R selective agonists with anticipated IND submissions approaching in late 2026 and early 2027.
Read more →PTN▼ -16%on this newsshared move
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies reported its fiscal third quarter 2026 financial results, highlighting advancements in its MC4R-based obesity programs. The company aims to submit IND applications for its MC4R selective peptide agonist and oral small molecule candidates in 2026 and 2027, respectively. Financially, Palatin recognized $3.9 million in collaboration revenue and reduced its net loss to $1.4 million, reflecting improved operational efficiency.
Read more →PTNPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies has reported its financial results for the second quarter of fiscal year 2026, highlighting advancements in its MC4R-based obesity programs. The company is set to initiate clinical evaluations for its oral and long-acting peptide MC4R agonists. Despite a net loss of $7.3 million, Palatin has strengthened its balance sheet through a successful public offering and aims to address significant unmet medical needs in obesity treatment.
Read more →PTNPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway...
Palatin Technologies reported its financial results for Q2 FY2026, highlighting advancements in its MC4R-based obesity programs, including the oral small-molecule PL7737 and next-generation peptide agonists. The company completed an $18.2 million public offering, enhancing its financial stability. Despite a net loss of $7.3 million, Palatin remains focused on addressing unmet medical needs in obesity treatment, particularly for hypothalamic obesity and Prader-Willi syndrome.
Read more →PTNPalatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies reported strong financial results for the first quarter of fiscal year 2026, highlighting significant advancements in its obesity pipeline, particularly with the oral small molecule PL7737. The company successfully closed an $18.2 million public offering, enhancing its financial position and enabling continued development of its melanocortin-based therapies. Additionally, Palatin's stock has resumed trading on the NYSE American, marking a positive turnaround for the company.
Read more →PTN▲ +10.6%on this news· ran to +28% by day 3shared move
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Technologies announced the successful closing of an $18.2 million public offering, which included the full exercise of the underwriters' over-allotment option. The offering was well-received, with participation from key institutional investors and company executives. The proceeds will support the development of Palatin's obesity program and general corporate purposes. Additionally, the company has regained compliance with NYSE American listing standards.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Technologies has announced the pricing of an upsized public offering, raising $15.8 million. The offering includes common stock and warrants, with participation from institutional investors and company executives. The funds will support the development of its obesity program and help regain compliance with NYSE American listing standards. The offering is expected to close on November 12, 2025.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Technologies, Inc. presented promising data on the melanocortin receptor (MC4R) agonist PL7737 at ObesityWeek® 2025, showing its potential for significant weight loss and safety in preclinical models. Additionally, a Phase II study indicated that combining MC4R agonists with tirzepatide could enhance weight management without new safety issues. Ongoing studies are set to lead to an IND submission and clinical trials in early 2026. The company is committed to advancing innovative therapies for obesity, particularly for rare genetic conditions.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company advancing medicines that modulate the melanocortin receptor system, today...
Palatin Technologies has achieved a significant milestone in its collaboration with Boehringer Ingelheim, earning a €5.5 million payment. This partnership focuses on developing innovative treatments targeting the melanocortin receptor system for retinal diseases, including diabetic retinopathy. The collaboration aims to address critical unmet medical needs in diabetes-related eye conditions.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Earns 5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment
Palatin Technologies has achieved a research milestone in its collaboration with Boehringer Ingelheim, earning a payment of $6.5 million. The focus of this collaboration is on developing first-in-class treatments targeting melanocortin receptors for retinal diseases like diabetic retinopathy. Palatin aims to address significant unmet medical needs and has the potential for substantial future milestone payments and royalties under the partnership. This achievement reflects Palatin's strategy to enhance its pipeline of melanocortin receptor agonists through strategic collaborations.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Announces 1-for-50 Reverse Stock Split PRINCETON, NJ
Palatin Technologies, Inc. has announced a 1-for-50 reverse stock split effective August 8, 2025, to improve its share price and comply with NYSE American listing requirements. The adjustment will reduce the number of outstanding shares, consolidating every 50 shares into one. Shareholders approved this measure during the annual meeting. The company continues to focus on developing innovative medicines targeting significant unmet medical needs, although future outcomes depend heavily on clinical trial results and market conditions.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Announces 1-for-50 Reverse Stock Split
Palatin Technologies has announced a 1-for-50 reverse stock split effective August 8, 2025. This action is taken to boost the market price of its shares, assisting compliance with NYSE American's Listing Qualifications. The adjusted shares will begin trading under the new ticker PTNTD on the OTCQB Market starting August 11, 2025. Shareholders approved this decision at the annual meeting held on July 25, 2025. The reverse stock split will consolidate shares and provide cash for any fractional shares.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Palatin Technologies announced promising preclinical efficacy data for their oral MC4R agonist PL7737 in obesity treatment. In rodent models, PL7737 demonstrated significant weight loss, both as a monotherapy and in combination with tirzepatide. The company plans to begin clinical trials in late 2025, with preliminary data expected in early 2026. Additionally, PL7737 has received orphan drug designation for treating leptin receptor deficiency-related obesity.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Technologies reported strong operational results for Q3 of FY 2025, highlighting advancements in its obesity and ocular programs. The Phase 2 obesity study demonstrated effective weight reduction with a combination of therapies, while the Phase 3 ocular program achieved significant symptom resolution in dry eye patients. Despite these achievements, the company faces challenges such as the suspension and potential delisting from the NYSE American due to low stock price and reduced cash reserves. Moving forward, Palatin is focusing on securing funding to support ongoing operations and strategic initiatives.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Technologies presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for the treatment of diabetic retinopathy at the ARVO Annual Meeting. The findings indicate these compounds can resolve inflammation, stabilize the blood-retinal barrier, and protect retinal ganglion cells. Notably, both agents demonstrated efficacy through multiple administration routes, including topical delivery, suggesting significant potential for earlier treatment interventions. Ongoing development of these melanocortin receptor-targeting therapies is supported by the results, highlighting their innovative approach to managing diabetic retinopathy.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Technologies, Inc. announced the closing of a reduced public offering, securing approximately $1.1 million in gross proceeds. The offering involved 7,324,119 shares of common stock along with accompanying warrants. The company plans to use the net proceeds primarily for working capital and general corporate purposes. This event marks a continued effort by the company to bolster its financial standing and support its development endeavors.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Technologies presented promising data on PL9643 during the Phase 3 MELODY-1 trial for dry eye disease at the ARVO 2025. The analysis showed that PL9643 could achieve full symptom resolution across multiple endpoints, demonstrating significant efficacy as early as two weeks into treatment. The therapy also exhibited a strong safety profile, with adverse events comparable to vehicle control. These findings suggest that PL9643 could be a first-in-class treatment, addressing unmet needs in the dry eye disease market.
Read more →PTN▼ -44.6%on this news· ran to +6394% by day 1shared move
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice The Company Intends to Request a Review of the Delisting Determination CRANBURY, NJ
Palatin Technologies announced it will transition to the OTC Pink Market after receiving a delisting notice from NYSE American due to the low selling price of its stock. Trading on the NYSE American has been suspended, and the company plans to appeal the delisting determination. CEO Carl Spana expressed disappointment but maintained confidence in the company's valuable assets and continued commitment to its business plan. Palatin has until May 14, 2025, to file its appeal.
Read more →PTN▼ -44.6%on this news· ran to +6394% by day 1shared move
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Palatin Technologies, Inc. announced its expectation to close a public offering of $11.5 million, aiming to address a delisting notice from NYSE American. The funding will support the advancement of its obesity program and ongoing business development initiatives. The company is optimistic about meeting compliance with listing standards and has plans for IND applications in late 2025, with initial clinical data anticipated in mid-2026. There is also significant interest in collaborations related to its ocular assets.
Read more →PTN▼ -44.6%on this news· ran to +6394% by day 1shared move
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Palatin Technologies, Inc. has announced the pricing of a public offering that could raise up to $23 million, with an initial $11.5 million upfront. Institutional investors, including company executives, are participating in this offering that includes common stock shares and various series of warrants. The additional funds from exercise of the Series G Warrants are uncertain, and the company intends to use the proceeds for working capital and development of its obesity program. The closing is anticipated around May 8, 2025, subject to standard conditions.
Read more →PTN▼ -44.6%on this news· ran to +6394% by day 1shared move
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin...
Palatin Technologies has received a delisting notice from NYSE American due to low stock prices, leading to immediate suspension of trading. The company will transition its shares to the OTC Pink Market starting May 8, 2025, and plans to appeal the delisting decision. CEO Carl Spana expressed disappointment but remains committed to advancing the company's business plan.
Read more →PTN▼ -17.5%on this news· ran to +4967% by day 3shared move
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Palatin Technologies, Inc. has announced promising preclinical data for PL9588, a melanocortin receptor agonist, at the ARVO 2025 Annual Meeting. The findings indicate that PL9588 can lower intraocular pressure while also providing neuroprotection, addressing a significant gap in current glaucoma treatments. The dual-action mechanism positions PL9588 as a potential next-generation therapy for glaucoma, with encouraging results from ongoing research. Palatin's strategic focus on this compound suggests a commitment to innovate within the ocular therapeutic space.
Read more →PTNPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Palatin Technologies has announced promising results from its updated Phase 3 MELODY-1 clinical trial for PL9643, a novel treatment for dry eye disease. The trial demonstrated significant symptom resolution across 6 of 13 endpoints, a benchmark not met by existing FDA-approved therapies. Notably, symptom improvement was statistically significant as early as two weeks and continued through 12 weeks. Given its impressive efficacy and safety profile, PL9643 may represent a significant advancement in treating dry eye disease, addressing a critical unmet medical need.
Read more →PTN▼ -10.6%on this news· ran to -21% by day 3
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Palatin Technologies announced positive results from its BMT-801 Phase 2 obesity study, which examined the effects of the co-administration of the MC4R agonist bremelanotide with tirzepatide. The study found that bremelanotide matched or exceeded tirzepatide in appetite suppression and provided significant benefits in weight maintenance post-therapy. Additionally, the trial reported notable improvements in patient-reported outcomes related to appetite, fullness, and satiety. Further clinical developments are anticipated in the coming quarters, aiming to expand on these findings.
Read more →PTN▲ +15.4%on this news· ran to +33% by day 3shared move
Palatin Appeals NYSE American Notice of Delisting
Palatin Technologies, Inc. has appealed the NYSE Regulation's decision to delist its common stock, which is currently allowed to continue trading on the NYSE American during the appeal process. The company has not met the stockholders' equity requirements by the compliance plan deadline. Palatin is proactively addressing this challenge by accelerating out-licensing discussions and seeking strategic funding opportunities. The outcome of the appeal will be determined by the NYSE Listings Qualifications Panel within 60 to 90 days.
Read more →PTNPalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal CRANBURY, NJ
Palatin Technologies, Inc. has received a notice from NYSE American regarding the delisting of its common stock due to non-compliance with stockholder equity requirements. The company is in a compliance plan that expired on April 10, 2025, without demonstrating the necessary financial improvements. Palatin intends to appeal the delisting decision by the deadline of April 25, 2025, while continuing trading during the appeal process. However, there is no guarantee that compliance will be achieved before any potential hearing.
Read more →PTNPalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules...
Palatin Technologies, Inc. announced that it has received a notice from NYSE American regarding the commencement of delisting proceedings due to non-compliance with stockholders' equity requirements. The company intends to appeal this decision and will continue trading during the appeal process. However, there is no guarantee that compliance will be regained before any hearing occurs.
Read more →PTNPalatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Palatin Technologies has announced promising results from its Phase 2b BREAKOUT study on a melanocortin agonist for patients with Type 2 diabetic nephropathy. The study revealed that 71% of participants achieved a notable reduction in kidney damage, and similar percentages showed improvement in kidney function metrics. The data will be showcased at the National Kidney Foundation Spring Meeting, affirming the potential of the melanocortin platform in addressing unmet medical needs in kidney health.
Read more →PTN▼ -12%on this news· ran to -26% by day 1
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies announced the successful results of its Phase 2 obesity study, where the combination of the MC4R agonist bremelanotide and the GLP-1/GIP agent tirzepatide met its primary endpoint with a statistically significant weight loss. Participants in the co-administered group saw a 4.4% reduction in weight compared to 1.6% in the placebo group. The study indicates that the synergistic effect of both drugs can improve weight loss outcomes without increasing safety concerns. However, many participants experienced weight regain post-treatment, a common occurrence with GLP-1 therapies.
Read more →PTN▼ -5.4%on this news· ran to -23% by day 3shared move
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically...
Palatin Technologies announced positive topline results from its Phase 2 study of PL8177, a melanocortin-1 receptor agonist for ulcerative colitis. The study found that 33% of patients achieved clinical remission compared to 0% on placebo, and 78% showed a significant clinical response. The treatment was well tolerated with no adverse events, and discussions for licensing are advancing with major pharmaceutical companies.
Read more →PTN▼ -5.4%on this news· ran to -23% by day 3shared move
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo aft
Palatin Technologies has announced positive topline results from its Phase 2 study of PL8177, an oral melanocortin-1 receptor agonist, in patients with active ulcerative colitis. The study demonstrated that 33% of the treated patients achieved clinical remission compared to none in the placebo group. Additionally, 78% of those treated showed a significant clinical response. The drug was well-tolerated, and no adverse events were reported, supporting its potential as a safe alternative to current therapies. The strong data from the trial is attracting interest from major pharmaceutical companies for potential licensing deals.
Read more →PTNPalatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies, Inc. has announced that its oral MC4R agonist, PL7737, has received FDA orphan drug designation for treating obesity due to leptin receptor deficiency. This designation is significant for developing a more convenient oral option compared to the existing injection treatment for this rare genetic disorder. Palatin plans to submit an Investigational New Drug (IND) application by the fourth quarter of 2025 and anticipates clinical data release in the first half of 2026. The company is also exploring other indications for PL7737, demonstrating a commitment to addressing unmet medical needs in obesity treatment.
Read more →PTN▲ +7.1%on this news
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Palatin Technologies reported its financial results for the second quarter of fiscal year 2025, marked by the completion of the database lock for its Phase 2 obesity co-administration study. This study tests the effectiveness of bremelanotide alongside tirzepatide in treating obesity. With topline data expected by the end of February 2025, the company expresses optimism about innovative treatment options for obesity and other rare diseases. Furthermore, Palatin is exploring various collaborative and licensing opportunities as it prepares for multiple clinical trials in the upcoming year.
Read more →PTN▼ -8.8%on this newsshared move
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Palatin Technologies, Inc. is set to announce its second quarter fiscal year 2025 results on February 13, 2025, before the U.S. markets open. A teleconference and webcast, hosted by its executive team, will follow at 11:00 a.m. ET the same day for a review of the operating results and updates on its development programs. The live audio webcast will be accessible through the company's website.
Read more →PTN▲ +6.1%on this newsshared move
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Palatin Technologies, Inc. announced a $4.7 million registered direct offering and concurrent private placement, involving the sale of 4,688,000 shares at $1.00 each. The offering aims to support general corporate purposes and is expected to close around February 10, 2025. A.G.P./Alliance Global Partners is the lead placement agent for this transaction.
Read more →PTN▲ +6.1%on this newsshared move
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement CRANBURY, N.J.
Palatin Technologies has announced a $4.7 million registered direct offering and concurrent private placement to bolster its financial position. The company will sell 4,688,000 shares at $1.00 each to a single healthcare-focused institutional investor, along with warrants for the same number of shares. The proceeds are intended for general corporate purposes, with the offering expected to close around February 10, 2025. This move reflects Palatin's ongoing commitment to developing innovative medicines centered on the melanocortin receptor system.
Read more →PTN▲ +14.3%on this newsshared move
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Technologies, Inc. has completed its Phase 2 clinical study, BMT-801, which investigates the co-administration of MC4R bremelanotide and GLP-1/GIP tirzepatide for obesity treatment. The study enrolled 113 patients, significantly exceeding the initial target due to high demand. Topline results are anticipated later this quarter, with expectations that the data will demonstrate effective weight loss outcomes. The findings will inform future clinical programs aimed at treating obesity and related disorders.
Read more →PTNPalatin Provides Update on Anticipated 2025 Corporate Milestones
Palatin Technologies, Inc. has announced an update on its anticipated corporate milestones for 2025, focusing on the Phase 2 BMT-801 clinical study of bremelanotide in combination with tirzepatide for obesity treatment. The company expects to report topline results in the first quarter of 2025 and plans to commence multiple clinical trials in the second half of the year. Additionally, ongoing discussions for licensing collaborations emphasize growing interest in Palatin's innovative therapies targeting obesity and other medical conditions.
Read more →PTN▲ +14.7%on this news· ran to +32% by day 3
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Technologies, Inc. announced promising results from the Phase IIb BREAKOUT study, which evaluated bremelanotide in patients with Type 2 diabetic nephropathy. The study reported that 71% of participants achieved significant protein reduction and stabilized kidney function. The treatment increased urinary VEGF levels in 37.5% of patients, indicating potential therapeutic benefits. Although well tolerated, the study's findings may be limited by the small patient population.
Read more →PTN▼ -5%on this newsshared move
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Palatin Technologies has announced the exercise of warrants that will generate approximately $3.4 million in gross proceeds. The agreement involves an institutional investor exercising outstanding warrants from June 2024 and October 2023. The funds will be utilized for working capital and general corporate purposes, with the transaction expected to close on December 17, 2024.
Read more →PTN▼ -5%on this newsshared move
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds CRANBURY, N.J.
Palatin Technologies, Inc. has announced the exercise of outstanding warrants resulting in approximately $3.4 million in gross proceeds. The agreement involves an institutional investor exercising a portion of its warrants issued in June and October of 2023. Proceeds from this transaction are intended for working capital and general corporate purposes. The closing of the transaction is expected on or about December 17, 2024, subject to customary closing conditions.
Read more →PTN▲ +14.6%on this news
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Palatin Technologies has completed patient enrollment for its Phase 2 study of PL8177, an oral melanocortin agonist targeting ulcerative colitis. This study aims to assess the drug's safety, efficacy, and tolerability among adults with active disease, with results expected in early 2025. Promising preclinical data indicates PL8177's potential to improve colon health and reduce inflammation without the adverse effects associated with current standard treatments. The company intends to seek out-licensing opportunities for the UC program following data release.
Read more →PTN▼ -10.1%on this news· ran to -22% by day 3
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results Obesity programs: o Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates o Phase
Palatin Technologies reported its first quarter financial results for fiscal year 2025, emphasizing its focus on obesity treatments. The company announced the completion of patient enrollment for its Phase 2 clinical study of BMT-801, with results expected in the first quarter of 2025. While the reported net loss increased to $7.8 million, the focus on developing first-in-class obesity therapies remains a key strategy amidst ongoing discussions about its non-obesity programs. Cash reserves notably declined due to prior product sales elimination.
Read more →PTN▼ -10.1%on this news· ran to -22% by day 3
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2...
Palatin Technologies reported its fiscal Q1 2025 results, emphasizing its focus on obesity treatments, including the Phase 2 BMT-801 study. Patient enrollment was completed in October 2024, with topline results expected in early 2025. The company is also exploring strategic options for its non-obesity programs while facing a net loss of $7.8 million for the quarter.
Read more →PTN▲ +12.1%on this news
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Palatin Technologies, Inc. (NYSE American: PTN) is set to announce its first quarter fiscal year 2025 operating results on November 14, 2024. This announcement will be followed by a conference call and live audio webcast at 11:00 a.m. ET, where the company's executive management will discuss the operating results and updates on ongoing programs. The results will be released before the U.S. markets open that day.
Read more →PTNPalatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Technologies has presented promising preclinical data on its oral melanocortin 4 receptor (MC4R) agonist, PL7737, at ObesityWeek 2024. The data indicates that PL7737 significantly reduces food intake and body weight in diet-induced obese mice. Following its positive preclinical findings, Palatin is preparing to initiate multiple clinical trials for this obesity treatment in 2025, highlighting both the potential and unmet medical needs in obesity management. The company aims to target various metabolic disorders through its innovative approach to obesity treatments.
Read more →PTNPalatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Palatin Technologies has announced the completion of patient enrollment in its Phase 2 clinical study assessing the co-administration of bremelanotide and tirzepatide for obesity treatment. The study exceeded its target enrollment of 60 patients due to strong demand. Topline results are anticipated by March 2025, and the data gathered will provide insights to enhance Palatin's obesity treatment programs, which focus on the melanocortin receptor mechanism. This trial is particularly significant given the increasing prevalence of obesity and the need for effective treatment options.
Read more →PTNInflammatory Disease Healing Data via Palatin
Palatin Technologies presented positive data on melanocortin receptor agonists for treating inflammatory diseases at the Peptide Therapeutics Symposium. Notable findings include the effectiveness of PL9643 in dry eye disease, with a statistically significant impact on symptoms, and promising results from preclinical studies of PL8177 and PL9654 in ulcerative colitis and retinal disease, respectively. The company anticipates further developments and clinical trials for these candidates in the near future, reflecting strong potential for their therapeutic applications.
Read more →PTNPalatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Palatin Technologies presented data on highly selective melanocortin 4 receptor (MC4R) agonists that aim to reduce skin pigmentation side effects. The findings were shared at the 19th Annual Peptide Therapeutics Symposium, where the company's R&D lead emphasized the potential of these agonists in treating obesity. Clinical trials for these new compounds are expected to commence in 2025. Additionally, Palatin is currently involved in a Phase 2 trial combining an MC4R agonist with another obesity treatment, with results anticipated in early 2025.
Read more →PTNPalatin Receives Notice of Non-Compliance from NYSE American Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies, Inc. has received a notice of non-compliance from NYSE American due to insufficient stockholders' equity. The company has submitted a plan to regain compliance by April 10, 2025, which has been accepted by the Exchange. While Palatin is exploring funding options, there is no immediate impact on its stock trading or business operations.
Read more →PTNPalatin Receives Notice of Non-Compliance from NYSE American CRANBURY, NJ
Palatin Technologies, Inc. announced it received a notice of non-compliance from NYSE American, due to not meeting stockholders' equity requirements. The company is permitted to continue its listing while it follows a plan to regain compliance by April 10, 2025. Despite the notice, there is no immediate impact on trading of Palatin's stock, and the company is exploring funding options to achieve compliance going forward.
Read more →PTNPalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar ...
Palatin Technologies reported its financial results for the fourth quarter and fiscal year ended June 30, 2024, highlighting advancements in several clinical programs. The company has commenced patient dosing in a Phase 2 study for obesity and received FDA confirmation on protocols for dry eye disease trials. Despite a reported net loss, Palatin anticipates key milestones in the coming quarters.
Read more →PTNPalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones Obesity: Phase 2 Clinical Study with Melanocortin-4 Rece
Palatin Technologies reported its financial results for the fourth quarter and the year ending June 30, 2024, highlighting various clinical program updates and anticipated milestones. The company is set to complete patient enrollment in its Phase 2 study of an MC4R agonist plus a GLP-1 agonist for obesity by early Q4 2024, with topline data expected in early Q1 2025. Additionally, the FDA has confirmed protocols for several other studies, including the Phase 3 trial of PL9643 for dry eye disease. Financially, Palatin noted a decline in revenue from Vyleesi sales compared to the previous year, impacting its overall fiscal performance.
Read more →PTNPalatin to Report Fourth Quarter and Fiscal Year End 2024 Results
Palatin Technologies, Inc. is scheduled to announce its fourth quarter and fiscal year end 2024 operating results on October 1, 2024. The company will host a conference call at 11:00 AM ET to review the results and update on ongoing development programs. This event aims to provide transparency to investors about the company's performance and future direction.
Read more →PTNPalatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Palatin Technologies, Inc. has provided an update on its ongoing clinical programs and strategic priorities, highlighting several anticipated milestones. The FDA has confirmed protocols and endpoints for the Phase 3 trials of PL9643 aimed at treating dry eye disease, with patient enrollment expected to start in Q4 2024. Additionally, the company has initiated a Phase 2 study involving an MC4R agonist and GLP-1 for obesity, aiming for results in early 2025. Palatin is actively engaging in collaborations to support various development programs, indicating a proactive approach in advancing its clinical pipeline.
Read more →PTN▲ +9.4%on this news
FDA Confirms Acceptability of Palatin
The FDA has confirmed the acceptability of the clinical trial protocols for Palatin Technologies' PL9643, which is aimed at treating dry eye disease (DED). Patient enrollment for the remaining Phase 3 pivotal trials, MELODY-2 and MELODY-3, is expected to begin in Q4 2024, with topline results anticipated by year-end 2025. Following the success of MELODY-1, which met several statistically significant endpoints, Palatin is optimistic about bringing a new treatment option to patients who find existing therapies inadequate. A new drug application (NDA) submission is projected for the first half of 2026 if recruitment goals are met and the trials yield positive results.
Read more →PTNFirst Patient Dosed in Phase 2 Clinical Study of Palatin
Palatin Technologies has initiated patient dosing in its Phase 2 clinical trial, investigating the co-administration of bremelanotide and tirzepatide for obesity treatment. The trial is designed to include up to 60 patients and aims to assess both safety and efficacy. Palatin anticipates full enrollment by Q3 2024, with topline results expected in early 2025. The study's focus on combining different mechanisms to improve treatment outcomes reflects a strategic approach to address obesity, a growing public health concern.
Read more →PTNPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds CRANBURY, N.J.
Palatin Technologies has announced the exercise of certain outstanding warrants with an institutional investor, resulting in gross proceeds of approximately $6.1 million. The investor will exercise warrants from November 2022 and October 2023 at an amended price of $1.88 per share. In return, Palatin will issue new Series A and B warrants to the investor, with various terms of exercise. The transaction is expected to close by June 24, 2024, subject to customary conditions, and the funds are intended for working capital and general corporate purposes.
Read more →PTNPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Palatin Technologies has announced a warrant inducement agreement with an institutional investor, resulting in the exercise of warrants for approximately $6.1 million. The agreement involves the exercise of warrants issued in November 2022 and October 2023, with an amended exercise price of $1.88 per share. The proceeds will be used for working capital and corporate purposes, and the transaction is expected to close on June 24, 2024.
Read more →PTN▼ -9.2%on this newsshared move
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Palatin Technologies has announced the initiation of a Phase 2 clinical study for bremelanotide co-administered with a PDE5 inhibitor aimed at treating erectile dysfunction in patients who do not respond to PDE5i monotherapy. The study is designed to include approximately 50 patients, and topline data is anticipated by the end of 2024. This approach addresses a critical gap in treatment options, considering that around 30-40% of ED patients do not effectively respond to typical therapies like Viagra or Cialis. A Phase 3 clinical study is also planned for 2025 for a co-formulated version of bremelanotide and PDE5i.
Read more →PTN▲ +6.5%on this news
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Palatin Technologies has launched a Phase 2 clinical trial to study the efficacy and safety of bremelanotide for obesity in combination with tirzepatide. The trial, which has received FDA clearance, aims to enroll up to 60 patients and is designed to assess results by the end of 2024. This initiative could offer an alternative weight loss treatment to patients who face challenges with current GLP-1 agonists, which often have discontinuation rates due to side effects.
Read more →PTN▼ -14.1%on this news
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results o Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
Palatin Technologies provided a corporate update alongside its financial results for the third quarter of fiscal year 2024, highlighting successful outcomes from the Phase 3 MELODY-1 clinical trial. The trial demonstrated statistical significance in pain relief and multiple secondary endpoints for PL9643, signaling potential for effective treatment of dry eye disease. The company also announced upcoming Phase 2 studies focusing on obesity and erectile dysfunction, with expected topline data release in the second half of 2024. Palatin is preparing for discussions with the FDA to support further development of its programs ahead of potential NDA submissions.
Read more →PTN▼ -14.1%on this news
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11...
Palatin Technologies reported positive results from its Phase 3 MELODY-1 study for PL9643, which met its co-primary endpoint for pain with statistical significance. The study also showed significant improvements in multiple secondary endpoints. The company is preparing for further clinical trials and discussions with the FDA regarding future studies and NDA submissions.
Read more →PTN▲ +14.6%on this news
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
Palatin Technologies, Inc. will announce its third quarter fiscal year 2024 results on May 15, 2024, prior to the U.S. market opening. An executive-led conference call and audio webcast will follow, providing a review of these results and updates on developmental programs. Interested parties can access the call and webcast via Palatin's website, offering an opportunity to gain insights into the company's operations and strategies.
Read more →PTN▲ +9.6%on this news
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies has announced FDA clearance for its IND application to evaluate the co-administration of bremelanotide and tirzepatide for obesity treatment. This Phase 2 clinical study is set to begin in mid-2024 and aims to demonstrate the safety and efficacy of the combination in achieving greater weight loss. Topline data from the trial is expected by the end of 2024. The company also plans to discuss its metabolic program and new treatment pathways in an upcoming virtual KOL event.
Read more →PTNPalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies is set to host a virtual KOL event on May 8, 2024, to discuss the potential of novel melanocortin receptor 4 agonists in treating obesity. The event will feature presentations from Dr. Jesse Richards, highlighting the need for alternative therapeutic approaches in obesity management. A Phase 2 clinical study is expected to begin mid-2024, with topline data anticipated by year-end. The discussion aims to shed light on combining melanocortin agonists with incretins for optimized treatment outcomes.
Read more →PTN▲ +14.8%on this news
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies has announced positive topline results from its Phase 3 MELODY-1 clinical trial for PL9643, a treatment for dry eye disease (DED). The trial, presented at the ASCRS conference, demonstrated statistically significant improvements in co-primary and secondary symptom endpoints. Notably, improvements were observed as early as two weeks into treatment, with a robust safety profile reported. Palatin is also engaging in discussions with the FDA regarding the regulatory approval process.
Read more →PTN▼ -38.3%on this news· ran to -50% by day 3
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Technologies announced positive results from its Phase 3 MELODY-1 trial for PL9643, a treatment for dry eye disease (DED). The trial met key symptom endpoints with statistical significance and showed excellent safety data. Although some sign endpoints did not achieve statistical significance, the overall results indicate promising efficacy. The company plans to consult with the FDA about the next steps in the regulatory approval process.
Read more →PTN▼ -23.9%on this news
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye...
Palatin Technologies reported its fiscal second quarter results, focusing on its melanocortin receptor system pipeline. The company anticipates topline data from several pivotal studies in 2024, including the MELODY-1 Phase 3 study for dry eye disease. Additionally, Palatin completed the sale of Vyleesi for up to $171 million, which strengthens its financial position as it advances multiple clinical trials.
Read more →PTN▼ -23.9%on this news
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline o PL9643 MELODY-1 Pivotal Ph
Palatin Technologies, Inc. has announced its financial results for the second quarter of fiscal year 2024, reporting a net loss of $7.8 million despite a significant increase in net product sales from Vyleesi. The company completed the divestiture of Vyleesi, allowing it to focus on its melanocortin receptor system pipeline, which includes several pivotal and phase 2 studies. Topline data from studies on dry eye disease, ulcerative colitis, and diabetic kidney disease are expected within the upcoming months. Additionally, Palatin is set to initiate clinical trials targeting obesity and male sexual dysfunction in early 2024.
Read more →PTN▲ +5.7%on this news
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Palatin Technologies, Inc. is set to announce its second quarter fiscal year 2024 operating results on February 15, 2024, prior to U.S. market opening. The company will hold a conference call and live audio webcast at 11:00 a.m. ET to discuss these results and provide updates on ongoing development programs. This event aims to give investors insights into the company's operational performance and strategic direction.
Read more →PTN▲ +7.7%on this news
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Technologies has announced the database lock for its pivotal Phase 3 clinical trial, MELODY-1, of PL9643, aimed at treating dry eye disease. The trial's success hinges on meeting either or both of its co-primary efficacy endpoints related to clinical signs and symptoms of the condition. With 575 patients enrolled across U.S. sites, the independent statisticians have started analyzing the data, and top-line results are anticipated in February 2024. The upcoming MELODY-2 and MELODY-3 studies are projected to begin patient enrollment in the latter half of 2024.
Read more →PTN▼ -14.3%on this newsshared move
Palatin Announces Closing of $10 Million Registered Direct Offering
Palatin Technologies, Inc. announced the successful closing of a registered direct offering generating approximately $10 million. The company sold 1,831,503 shares of common stock at a purchase price of $5.46 per share and issued warrants for additional shares. The net proceeds from this offering are intended for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction.
Read more →PTN▼ -10.6%on this news· ran to -31% by day 3shared move
Palatin Announces $10 Million Registered Direct Offering CRANBURY, NJ
Palatin Technologies, Inc. has announced a definitive agreement to raise $10 million through a registered direct offering. The deal involves selling approximately 1.83 million shares of common stock and associated warrants at a price of $5.46 per share. The gross proceeds are intended for general corporate purposes and are expected to close on or about February 1, 2024, subject to customary conditions. Analysts note uncertainties linked to the completion of the offering and potential market fluctuations affecting the company's future performance.
Read more →PTN▼ -10.6%on this news· ran to -31% by day 3shared move
Palatin Announces $10 Million Registered Direct Offering Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Palatin Technologies, Inc. has announced a definitive agreement for a registered direct offering, selling 1,831,503 shares at $5.46 each, aiming to raise approximately $10 million. The offering is expected to close around February 1, 2024, subject to customary conditions. Proceeds will be used for general corporate purposes.
Read more →PTN▲ +12.7%on this news
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Palatin Technologies provided a corporate update outlining its strategic priorities and anticipated clinical milestones for 2024. The company plans to release topline data for its Phase 3 study on dry eye disease and an interim analysis for its Phase 2 study on ulcerative colitis, both expected in early 2024. Additionally, Palatin is preparing to initiate several Phase 2 studies targeting obesity and male sexual dysfunction. The recent divestiture of its asset Vyleesi is part of the company’s focus on developing therapeutics that modulate the melanocortin receptor system.
Read more →PTNPalatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies has completed the sale of its product Vyleesi to Cosette Pharmaceuticals for up to $171 million. The deal includes an upfront payment of $12 million and potential sales-based milestones of up to $159 million. Palatin will now focus on its clinical pipeline, including ongoing studies for dry eye disease and ulcerative colitis.
Read more →PTNPalatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 Million Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development a
Palatin Technologies has completed the sale of Vyleesi to Cosette Pharmaceuticals for up to $171 million, consisting of a $12 million upfront payment and additional milestone payments based on sales. This strategic divestiture aligns with Palatin's focus on enhancing its pipeline centered on the melanocortin receptor system. Vyleesi is recognized as the first and only on-demand treatment for premenopausal women with hypoactive sexual desire disorder. Cosette aims to make Vyleesi a priority in their women's health portfolio, serving a significant patient population in the U.S.
Read more →PTN▼ -8.3%on this newsshared move
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American CRANBURY, NJ
Palatin Technologies, Inc. received notice from NYSE American approving its compliance plan with listing standards. The company is required to meet specific stockholder equity thresholds by April 10, 2025, to avoid delisting. Palatin assured stakeholders that it will continue trading on the Exchange and is exploring funding avenues to ensure compliance. The approval does not affect current business operations or trading status.
Read more →PTN▼ -8.3%on this newsshared move
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies, Inc. has received notice from NYSE American approving its compliance plan to meet listing standards. The company must regain compliance by April 10, 2025, or face potential delisting. Despite recent losses, Palatin is exploring funding options and will continue to be listed during the compliance period.
Read more →PTNPalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) o 570 Patients Enrolled o Topline Data Currentl
Palatin Technologies reported its first quarter financial results for FY 2024, noting the completion of patient enrollment in its Phase 3 MELODY-1 study for Dry Eye Disease. Despite a net loss of $5.9 million, the company demonstrated significant revenue growth, with gross product revenue increasing by 11% and net revenue up 20% over the previous quarter. Upcoming clinical developments include an interim analysis for its Phase 2 study of oral PL8177 in ulcerative colitis expected in early 2024. The company is also looking forward to initiating two new clinical studies later in the quarter.
Read more →PTNPalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar...
Palatin Technologies reported its fiscal first quarter 2024 financial results, highlighting the completion of enrollment in its Phase 3 PL9643 study for dry eye disease with 570 patients. The company anticipates topline data by late 2023. Vyleesi continues to show strong sales growth, with net product revenue increasing by 20% over the previous quarter. Upcoming clinical studies are set for early 2024, including a Phase 2 study for ulcerative colitis.
Read more →PTNPalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Palatin Technologies, Inc. is set to announce its first quarter fiscal year 2024 operating results on November 14, 2023. This announcement will precede a conference call where the executive management team will discuss the results and provide updates on ongoing programs. Investors can participate in the call and access the webcast through Palatin's website, indicating the company’s commitment to investor relations and transparency.
Read more →PTNPalatin Announces Closing of $5 Million Registered Direct Offering
Palatin Technologies, Inc. has completed a registered direct offering, raising approximately $5 million by issuing 2,358,491 shares of common stock at a price of $2.12 per share. The company intends to use the net proceeds for general corporate purposes, which could strengthen its financial position. This offering included warrants that can be exercised after six months, allowing further capital inflow. H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction.
Read more →PTN▼ -13.8%on this newsshared move
Palatin Announces $5 Million Registered Direct Offering
Palatin Technologies, Inc. has entered into an agreement for a registered direct offering, intending to sell 2,358,491 shares of common stock at a price of $2.12 per share. This offering will generate approximately $5 million in gross proceeds, which will be used for general corporate purposes. The closing of the offering is anticipated to occur around October 24, 2023, pending customary closing conditions. Additionally, warrants for the purchase of the same number of shares are included, which will be exercisable within a defined timeframe.
Read more →PTN▼ -13.8%on this newsshared move
PTN - Palatin Announces $5 Million Registered Direct Offering CRANBURY, N.J.
Palatin Technologies, Inc. announced a $5 million registered direct offering involving the sale of 2,358,491 shares of common stock at a price of $2.12 each. The offering is led by H.C. Wainwright & Co. and is expected to close around October 24, 2023, subject to customary conditions. The proceeds will be used for general corporate purposes, which could enhance the company's operational capabilities. The accompanying warrants will be offered under specific regulatory exemptions and are contingent on stockholder approval.
Read more →PTN▲ +22.5%on this news· ran to +39% by day 1shared move
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Palatin Technologies reported strong preliminary results for the first quarter of fiscal year 2024, highlighting a significant increase in Vyleesi product revenue. Gross product revenue reached $4.6 million, marking an 11% increase compared to the previous quarter and a remarkable 100% increase year-over-year. Net product revenue also saw substantial growth of 18% over the previous quarter and 137% year-over-year, alongside a notable rise in prescriptions. However, Palatin issued a reminder that these preliminary figures may change and should not overly influence investor decisions.
Read more →PTNPalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Palatin Technologies announced positive preclinical data for its melanocortin-4 receptor (MC4R) agonist, PL8905, in combination with a GLP-1 agonist, demonstrating enhanced weight loss and glucose control. The results were presented at the Peptide Therapeutics Symposium, and a clinical study is expected to begin in the first quarter of 2024. This combination therapy approach aims to address high discontinuation rates seen in existing obesity treatments by promoting long-term weight loss with improved tolerability. The data indicates that dual administration may yield better results than monotherapy, with significant effects observed in preclinical trials.
Read more →PTNPalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Palatin Technologies presented positive data on oral PL8177 at the UEG 2023 conference, indicating its potential to improve the health of diseased colons in ulcerative colitis patients. The findings support ongoing Phase 2 studies and demonstrate PL8177's effectiveness in resolving inflammation without the safety risks associated with traditional immunosuppressive treatments. The study shows a favorable mechanism of action, marking a significant advancement for the drug's development and its application in addressing inflammatory bowel diseases.
Read more →PTNPalatin Receives Notice of Non-Compliance from NYSE American Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, NJ
Palatin Technologies, Inc. has received a notice from NYSE American indicating non-compliance with the exchange's listing standards due to insufficient stockholders' equity. The company is now required to submit a plan to regain compliance by November 9, 2023. If the plan is accepted, Palatin will maintain its listing while undergoing periodic reviews until compliance is achieved by April 2025. Despite this challenge, the company is actively exploring funding options to support its compliance efforts.
Read more →PTN▲ +13.2%on this news
Palatin Announces Preliminary Quarter Ended
Palatin Technologies announced preliminary financial results for the first fiscal quarter of 2024, indicating significant revenue growth for its product Vyleesi. The company reported $4.6 million in gross product revenue, representing an 11% increase from the previous quarter and a remarkable 100% growth compared to the same quarter last year. Vyleesi continues to be the only FDA-approved as-needed treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Despite positive trends in prescription growth and revenue, Palatin notes that the preliminary data has not been audited, indicating potential for adjustments in actual results.
Read more →PTN▼ -9.1%on this newsshared move
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar...
Palatin Technologies reported its financial results for the fourth quarter and fiscal year ended June 30, 2023. The company announced the completion of enrollment in its Phase 3 PL9643 study for Dry Eye Disease, with topline data expected in late 2023. Vyleesi showed significant revenue growth, with a 47% increase in net product revenue compared to the previous quarter. However, the company continues to face substantial operating expenses and reported a net loss of $10.7 million for the quarter.
Read more →PTN▼ -9.1%on this newsshared move
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled o Topl
Palatin Technologies reported its fourth quarter and fiscal year 2023 financial results, highlighting the completion of enrollment in the Phase 3 PL9643 clinical study for dry eye disease. The interim analysis showed statistically significant clinical efficacy and excellent safety profile. Net product revenue for Vyleesi has increased significantly, with a 47% rise over the prior quarter and a consistent growth trend over the last six quarters. The company anticipates topline data and final results in early 2024.
Read more →PTN▼ -5.7%on this news
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
Palatin Technologies, Inc. will announce its fourth quarter and fiscal year end 2023 operating results on September 28, 2023, prior to U.S. market opening. A conference call and live audio webcast will take place on the same day to discuss the results and update on developmental programs. Interested participants can access the webcast through Palatin's website, and various dial-in numbers are provided for audio participation.
Read more →PTNPalatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Palatin Technologies, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The presentation is scheduled for September 13, 2023, at 10:00 a.m. ET, with a live webcast available on the company's investor website. Palatin develops first-in-class biopharmaceutical medicines targeting melanocortin receptor systems aimed at addressing significant unmet medical needs. The company also plans to form marketing collaborations to enhance the commercial potential of its products.
Read more →PTNPalatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies has completed enrollment in its Phase 3 MELODY-1 study for PL9643, targeting dry eye disease. The study enrolled 570 patients, with topline results anticipated by late Q4 2023. Positive interim data indicates a favorable safety profile and potential efficacy across multiple symptoms. The company aims to submit a New Drug Application to the FDA by mid-2025.
Read more →PTNPalatin to Present at the H.C. Wainwright 25 th Annual Global Investment Conference Cranbury, NJ
Palatin Technologies, Inc. has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference scheduled for September 11-13, 2023, in New York. Management will present on September 13 at 10:00 a.m. ET, accompanied by a live webcast. The presentation focuses on their development of medicines based on molecules that modulate melanocortin receptor systems, aiming for treatments for diseases with significant unmet needs.
Read more →PTNPalatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrate
Palatin Technologies has successfully completed enrollment in its Phase 3 MELODY-1 study of PL9643, aimed at treating dry eye disease. A total of 570 patients were enrolled, with topline results expected by the end of 2023. An interim analysis of the first 120 patients indicated an excellent safety profile and the potential efficacy of PL9643 in addressing symptoms of dry eye disease. The study is crucial for patients dissatisfied with current treatments, and further results could lead to a New Drug Application submission by mid-2025.
Read more →PTN▼ -5.5%on this news
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies has launched a clinical program for bremelanotide, co-formulated with a PDE5 inhibitor, targeting erectile dysfunction (ED) in patients unresponsive to standard PDE5i treatments. The Phase 2 study is expected to begin in Q4 2023, aiming to provide a new therapeutic option for a significant patient population. This combination approach may enhance efficacy and reduce side effects.
Read more →PTN▼ -5.5%on this news
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment ~30-40% of ED patients do not respond to PDE5i treatment Published cli
Palatin Technologies has launched a clinical program to evaluate bremelanotide, a melanocortin receptor agonist, combined with a PDE5 inhibitor for treating erectile dysfunction (ED) in patients who do not respond to existing PDE5i therapies. This combination aims to offer a synergistic effect at lower doses, potentially minimizing side effects. The Phase 2 study is expected to begin in the fourth quarter of 2023 and seeks to address the significant unmet medical need among the 30-40% of ED patients who are non-responsive to traditional treatments.
Read more →PTN▲ +8.2%on this news· ran to +19% by day 1shared move
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies has announced that its partner Fosun Pharma reported the first commercial sale of Vyleesi in Hainan Province, China. At the same time, Kwangdong Pharmaceuticals has completed enrollment for a Phase 3 clinical study on the drug's efficacy for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) in South Korea, expecting results later this year. This paves the way for a potential marketing submission in South Korea in the first half of 2024. Palatin continues to pursue collaborations globally to expand Vyleesi's market presence.
Read more →PTN▲ +8.2%on this news· ran to +19% by day 1shared move
Palatin Provides Update on VYLEESI Collaborations Licensee Fosun Pharma Reports First Commercial Sale in China o First prescription dispensed in Chinese Hainan Province South Korean Licensee Kwangdong Pharmaceuticals Com
Palatin Technologies announced positive updates regarding Vyleesi collaborations, including the first commercial sale by Fosun Pharma in Hainan, China. The company reported that 93% of patients completed their Phase 3 trial for Vyleesi, with expected data to be released later this year. Kwangdong Pharmaceuticals has also completed patient enrollment for its own Phase 3 trial in South Korea, with the potential for a regulatory submission in early 2024. Additionally, Palatin has seen a sustained increase in Vyleesi prescriptions in the U.S., highlighting the growing traction of its product in the market.
Read more →PTN▲ +23.9%on this news· ran to +40% by day 3shared move
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's W
Palatin Technologies has announced a strategic partnership with UpScriptHealth to enhance awareness and access to Vyleesi, the first FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women. Through UpScriptHealth's Women's Telehealth Platform, Vyleesi will reach a vast patient base, providing education and treatment options for those suffering from HSDD. The partnership aims to solidify existing telehealth initiatives and improve healthcare accessibility for women.
Read more →PTN▲ +23.9%on this news· ran to +40% by day 3shared move
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi® Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies has partnered with UpScriptHealth to enhance awareness and access to Vyleesi, the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. This collaboration will utilize UpScriptHealth's Women's Telehealth Platform, reaching hundreds of thousands of patients. The partnership aims to improve education around HSDD and provide a significant treatment option.
Read more →PTNPalatin to Participate in Canaccord Genuity's 43 rd Annual Growth Conference Cranbury, NJ
Palatin Technologies, Inc. has announced its participation in the Canaccord Genuity 43rd Annual Growth Conference scheduled for August 9, 2023. The event will feature an Analyst led Fireside Chat, providing Palatin's management the chance to discuss their innovation in first-in-class medicines. The company focuses on developing products that target the melanocortin receptor system and aims to form marketing collaborations to enhance their products' commercial potential. A live webcast of the event will be accessible on their website, with a replay available for 30 days post-presentation.
Read more →PTNPalatin to Participate in Canaccord Genuity
Palatin Technologies, Inc. will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, at 5:00 p.m. ET. The event will feature an Analyst led Fireside Chat, which will be available via live webcast on Palatin's investors' website. This opportunity will allow the company to discuss its first-in-class medicines targeting the melanocortin receptor system and outline its strategy focused on forming marketing collaborations to optimize commercial potential.
Read more →PTNPalatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Palatin Technologies announced preliminary revenue results for Vyleesi in Q4 FY2023, reporting $4.1 million in gross revenue and $1.7 million in net revenue. The company experienced significant growth, with a 14% increase in prescriptions dispensed from the previous quarter and 89% from the same quarter last year. Palatin has maintained six consecutive quarters of double-digit growth, indicating a strong commercial strategy.
Read more →PTNPalatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi Product Revenue Results $4.1 million in Gross Product Revenue o 20% growth over 3Q23; 78% growth over 4Q22 $1.7 million in Net Product Revenue o 42% growth
Palatin Technologies announced preliminary revenue results for Vyleesi in the fourth quarter of fiscal 2023, reporting $4.1 million in gross product revenue, a 20% increase over the prior quarter, and a 78% increase year-over-year. Net product revenue reached $1.7 million, showing a 42% quarter-over-quarter and 122% year-over-year growth. Additionally, there was a 14% increase in prescriptions dispensed from the third quarter, marking six consecutive quarters of double-digit growth. The company continues to seek collaborations for expanding Vyleesi's market presence.
Read more →PTNPalatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference - Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy - Open Labe
Palatin Technologies presented promising preclinical data on their melanocortin agonist PL8177 at the International Podocyte Conference. The study demonstrated that PL8177 treatment preserves podocyte and proximal tubule cell expression in a rat model of diabetic nephropathy. As a result, it suggests a potential new therapeutic avenue for diabetic kidney disease, although further clinical trial development is ongoing with the Phase 2 BREAKOUT study currently enrolling patients.
Read more →PTNPalatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event o Analysis of Lead-In Population of Initial 120 P
Palatin Technologies reported its financial results for the third quarter of fiscal year 2023, highlighting significant progress in its clinical programs. The company revealed positive interim data from its Phase 3 study of PL9643 in patients with dry eye disease, demonstrating strong efficacy and safety. Additionally, Vyleesi achieved a 16% increase in net product revenue and has shown consistent growth over the last five quarters. Despite these advances, Palatin recorded a net loss of $7.1 million, though cash reserves are believed to be adequate for ongoing operations through 2023.
Read more →PTNPalatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. will announce its third quarter fiscal results on May 16, 2023. A conference call and audio webcast will follow, allowing executives to review performance and provide updates on ongoing developmental programs. The company focuses on creating innovative therapies aimed at addressing significant medical needs and aims to capitalize on its developments through strategic partnerships.
Read more →PTNPalatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
Palatin Technologies presented promising data on PL8177 at the Digestive Disease Week conference, showing its efficacy in animal models of inflammatory bowel disease. The oral formulation of PL8177 effectively targets the colon while avoiding systemic absorption, which could lead to favorable safety profiles. A Phase 2 clinical study is currently ongoing, with interim data expected in the second half of 2023, indicating potential advancements for treating ulcerative colitis. However, the company faces uncertainties related to trial outcomes and market competition.
Read more →PTN▲ +7.6%on this newsshared move
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar CRANBURY, N.J.
Palatin Technologies held a key opinion leader webinar discussing the PL9643 Phase 3 clinical trial outcomes for Dry Eye Disease. The presentation highlighted the promising data regarding the ocular tolerability and effectiveness of PL9643 eye drops in addressing symptoms of the condition. Industry experts participated in the discussion, enhancing the presentation's credibility. The replay of the webinar is accessible through Palatin's website.
Read more →PTNPalatin Technologies to Host Key Opinion Leader Webinar - Review of Phase 3 PL9643 Data for Dry Eye Disease - Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Webinar to take place on
Palatin Technologies is set to conduct a Key Opinion Leader (KOL) webinar on May 8, 2023, to review Phase 3 data for its drug PL9643, aimed at treating dry eye disease (DED). The data, recently showcased at an ophthalmology conference, reflects positive outcomes regarding the symptoms and signs of DED. The webinar will feature insights from company executives and experts, discussing the unmet medical needs associated with DED and the potential impact of PL9643. The ongoing Phase 3 study continues to recruit participants, with final results anticipated later in 2023.
Read more →PTNPalatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference - Poster data demonstrates PL9643 positive effects on signs and symptoms of
Palatin Technologies presented initial Phase 3 clinical data for PL9643 at the 2023 ARVO Annual Conference. The data indicated positive effects on multiple signs and symptoms of dry eye disease (DED), demonstrating both clinical efficacy and safety. The ongoing MELODY-1 trial continues to enroll patients, with topline data expected in the second half of 2023. PL9643's mechanism of action may provide a new therapeutic option, potentially setting it apart from existing treatments for DED.
Read more →PTN▼ -8.2%on this newsshared move
Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma - Poster presented at ARVO demonstrates PL9588 reduces intraocular pres
Palatin Technologies recently presented promising data on PL9588, a potential treatment for glaucoma, at the ARVO 2023 Annual Conference. The findings demonstrate that PL9588 effectively reduces intraocular pressure in normotensive rabbits, suggesting similar or better efficacy than existing glaucoma medications. Additionally, the melancortin receptor agonist may offer neuroprotective benefits. The company is optimistic about progressing PL9588 into clinical development as a novel therapeutic option for glaucoma patients.
Read more →PTNPALATIN ANNOUNCES PRELIMINARY THIRD QUARTER FISCAL 2023 VYLEESI PRODUCT REVENUE RESULTS $3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth ove
Palatin Technologies released preliminary third-quarter fiscal 2023 results for its product Vyleesi, showing promising growth metrics. Gross product revenue reached $3.4 million, marking a 31% increase over the previous quarter, while net product revenue soared by 22% to $1.2 million. Prescription growth also demonstrated strong performance, with a 27% increase quarter-over-quarter. Despite the positive results, the company cautions that these figures are preliminary and subject to change, which may affect investor confidence.
Read more →PTNPre-Clinical Data of Palatin
Palatin Technologies, Inc. announced the publication of a manuscript in the International Journal of Molecular Sciences detailing positive pre-clinical results for its melanocortin agonist PL8331 in models of retinal diseases. The study indicates that PL8331 can effectively resolve inflammation and protect retinal structures in experimental autoimmune uveoretinitis and diabetic retinopathy. The findings suggest a promising future for the use of melanocortin agonists in treating various inflammatory eye conditions, with potential implications for clinical development.
Read more →PTN▼ -9.2%on this news
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin
Palatin Technologies announced that a pre-clinical study of its oral formulation PL8177 has been published in Frontiers in Immunology. The study highlights the molecule's therapeutic effects for inflammatory bowel disease and indicates it is gut-restricted in both animal models and humans. Promising results show that PL8177 maintains colon structure and has a favorable safety profile, supporting its upcoming Phase 2 clinical trial for ulcerative colitis. This work contributes to the understanding of the melanocortin-1 receptor's potential in treating inflammatory conditions.
Read more →PTN▲ +18.5%on this newsshared move
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
Palatin Technologies, Inc. has announced the issuance of a new patent from the United States Patent and Trademark Office, which strengthens its intellectual property for Vyleesi (bremelanotide injection) used in treating hypoactive sexual desire disorder in women with controlled hypertension. The patent will remain effective until April 29, 2041, enhancing Palatin's market position. Vyleesi is currently the only FDA-approved medication for this condition, and the company is exploring collaborations to expand its distribution.
Read more →PTNPalatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing o Patient Enrollment on Track o Topline Results Cur
Palatin Technologies reported its financial results for the second quarter of FY 2023, highlighting ongoing progress in patient enrollment for its MELODY-1 Phase 3 trial targeting dry eye disease. The company noted a significant increase in Vyleesi's net product revenue and prescriptions dispensed compared to the previous quarter. Additionally, Palatin secured a $10 million direct offering and received $4.7 million in non-dilutive funding, supporting further development initiatives. Topline data for their clinical programs are expected later in 2023 and into 2024.
Read more →PTNPalatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
Palatin Technologies, Inc. will report its second quarter fiscal year 2023 results on February 15, 2023, prior to the U.S. financial market opening. The announcement will be followed by a live conference call at 11:00 a.m. ET on the same day, which will include discussions on the company's performance and ongoing development programs. All interested parties can access the call via a dedicated phone line or a webcast through Palatin's website.
Read more →PTNPalatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
Palatin Technologies has launched enrollment for the Phase 2b BREAKOUT Study, focusing on the use of bremelanotide to treat patients with diabetic kidney disease. The study aims to enroll up to 45 subjects and evaluates the efficacy of the drug in reducing protein levels in urine while maintaining podocyte function. This initiative reflects Palatin's ongoing commitment to developing treatments that modulate the melanocortin receptor system. If successful, this could provide new therapeutic options for the management of diabetic nephropathy, a major cause of end-stage renal disease.
Read more →PTNPalatin Receives $4.7 Million of Non-Dilutive Funding
Palatin Technologies, Inc. has announced the receipt of approximately $4.7 million in non-dilutive funding through New Jersey's Technology Business Tax Certificate Transfer Program. This funding is part of the Net Operating Loss (NOL) Program that allows qualified companies to convert tax losses into cash for growth. To date, Palatin has successfully secured about $18 million through this initiative, enabling them to support their research and development of first-in-class medicine targeting the melanocortin receptor system.
Read more →PTNPalatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
Palatin Technologies reported encouraging preliminary sales results for its Vyleesi product in the fiscal second quarter ended December 31, 2022. Net product revenue reached $1.0 million, representing a 15.4% increase over the previous quarter and a staggering 1,290% increase compared to the same quarter in 2021. Prescription rates also rose significantly, highlighting a positive trend in product acceptance and use among patients. However, these preliminary results have not been audited, making future adjustments likely.
Read more →PTN▼ -7.7%on this news
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis - DMC Recommended Study Si
ptn_ex991.htm EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis - DMC Recommended Study Size of 350 patients To
Read more →PTNPalatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference cal
Read more →PTN▲ +8.1%on this news· ran to +23% by day 3
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J., Oct. 24, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing
Read more →PTNFirst Patient Enrolled in Palatin
Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tolerability concerns Primary endpoint is the Mayo Endoscopic Subscore, which eva
Read more →PTNPalatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
Peer-reviewed paper presents notable mechanism of action findings Bremelanotide significantly increased sexual desire for up to 24 hours post administration CRANBURY, NJ, Oct. 17, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company
Read more →PTNPalatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J., Oct. 13, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a bi
Read more →PTNPalatin to Participate in Ladenburg Thalmann Healthcare Conference
CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will
Read more →PTNPalatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indication
Read more →PTN▼ -12.4%on this news· ran to -28% by day 3
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis - DMC Recommended Stu
ptn_ex991.htm EXHIBIT 99.1 Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis - DMC Recommended Study Sample Size of 350 Patien
Read more →PTNPalatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022
CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets. Palatin will also conduct a
Read more →PTN▲ +26.2%on this news· ran to +51% by day 3
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients CRANBURY, N.J., Sept. 8, 2022 /PRNews
Read more →PTN▼ -15.6%on this news· ran to -31% by day 3
Palatin Announces Intent to Effect Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activi
Read more →PTN▼ -6.5%on this news· ran to -24% by day 3shared move
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Results Currently Expected Second Quarter Calendar 2023 CRANBURY, N.J., Aug. 16,
Read more →PTNPalatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that
Read more →PTNPalatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currentl
ptn_ex991.htm EXHIBIT 99.1 Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calen
Read more →PTNPalatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock
CRANBURY, N.J., May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, to
Read more →PTNPalatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022
CRANBURY, N.J., May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call a
Read more →PTNPalatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
Posters highlight Palatin's ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J., May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate
Read more →PTNPalatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongoing - data expected 4Q 2022 CRANBURY, N.J., April 21, 2022 /PRNewswire/ -- P
Read more →PTNPalatin Hosting Key Opinion Leader Webinar on Dry Eye Disease
CRANBURY, N.J., March 3, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announc
Read more →PTN▲ +7.2%on this news
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update Initiated Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Expected Second Half Calenda
ptn_ex991.htm EXHIBIT 99.1 Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update Initiated Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Expected Second Half Calendar 2022 Approximately $47.3
Read more →PTN▼ -6.3%on this newsshared move
Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022
CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference
Read more →PTNPalatin Announces Presentation at the 2022 Crohn
CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced a presentation of th
Read more →PTNPalatin to Present at H.C. Wainwright BioConnect Conference
CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the
Read more →PTNPalatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the init
Read more →PTN▼ -16.4%on this news· ran to -39% by day 3
Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide
CRANBURY, N.J., Nov. 30, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced th
Read more →PTNPalatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the
ptn_ex991.htm EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022
Read more →PTNPalatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021
CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference c
Read more →PTNPalatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting
CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that its
Read more →PTN▼ -5.9%on this news
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update ● Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Qua
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 Ph
Read more →PTNPalatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the pre
Read more →PTNPalatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021
CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021, before the open of the U.S. financial markets. Palatin will also conduct a
Read more →PTNPalatin to Present Peptides Platform at the TIDES USA Conference
CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced
Read more →PTNPalatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference
CRANBURY, N.J., Sept. 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced
Read more →PTNPalatin Announces Presentation at the Eyecelerator@ASCRS Conference
CRANBURY, N.J., July 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced th
Read more →PTNPalatin Announces Adjournment of Annual Meeting of Stockholders ● Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock ● Scheduled to Reconvene
Palatin Announces Adjournment of Annual Meeting of Stockholders Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock Scheduled to Reconvene August 6, 2021, 9:00 am Eastern Daylight NJ July 8, 2021 Palatin Technologies, Inc. (
Read more →PTNPalatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
CRANBURY, N.J., June 29, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the
Read more →PTNPalatin Announces New Additions to Its Senior Leadership Team
CRANBURY, N.J., June 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the
Read more →PTNPalatin Announces Adjournment of Annual Meeting of Stockholders
CRANBURY, N.J., June 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021, has been adjourned until July 8, 2021 at 9:00 a.m. Eastern Daylight Time to solicit addi
Read more →PTNPalatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update ● Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 ɜ
Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis P
Read more →PTNPalatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications
CRANBURY, N.J., May 14, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it will ho
Read more →PTNPalatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021
CRANBURY, N.J., May 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and
Read more →PTNPalatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)
CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United
Read more →PTNPalatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced t
Read more →PTNPalatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual Conference
CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced t
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights
CRANBURY, N.J., Feb. 17, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, t
Read more →PTNForward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Palati
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi App
Read more →PTNPalatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021
CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conferenc
Read more →PTNPalatin Technologies Announces Filing of International Patent Application Claiming PL9643
CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced t
Read more →PTNPalatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Disease
CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced p
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update ● Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update Regained North American Rights to Vyleesi for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March Phase 2 Clinical Results of PL9643 for the Treatm
Read more →PTNPalatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020
CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference c
Read more →PTNPalatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Business Update ● $82.9 Million in Cash and Cash Equivalents at
Palatin Technologies, Inc. Announces Fourth Quarter Fiscal Year 2020 Financial Results and Provides a Business $82.9 Million in Cash and Cash Equivalents at June 30, Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi in July 2020 Resulted in Palatin
Read more →PTNPalatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020
CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets. Palatin will also conduct a con
Read more →PTNPalatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference
CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems,
Read more →PTNPalatin Technologies Participates In Canaccord Genuity
CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, a
Read more →PTNPalatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, to
Read more →PTNPalatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® Palatin Regains All Rights Company to Receive $16.3 Million from AMAG Teleconference and Webcast to be he
Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi Palatin Regains All Rights Company to Receive $16.3 Million from AMAG Teleconference and Webcast to be held on July 27, 2020 CRANBURY, NJ July 27, 2020 Palatin Techno
Read more →PTNPalatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
CRANBURY, N.J., July 8, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, to
Read more →PTNPalatin Technologies Announces Adjournment of Annual Meeting of Stockholders ● Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock ● Proposals 1, 2, 3 and 5
Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock Proposals 1, 2, 3 and 5 were approved at the Annual Meeting Scheduled to Reconvene July 23, 2020, 9:
Read more →PTNPalatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications
CRANBURY, N.J., June 23, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announc
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights ● Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 ● $89 Mi
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Dry Eye Disease Phase 2 Study Remains on Track Data $89 Million in Cash at March 31, 2020 Teleconference and Webcast to be held on May 12, 2020 CRANBURY, NJ May 12, 2020 P
Read more →PTNPalatin Technologies, Inc. to Report Third Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on May 12, 2020
CRANBURY, N.J., May 7, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and
Read more →PTNPalatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations
CRANBURY, N.J., April 30, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems,
Read more →PTNPalatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, t
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights — Dry Eye Disease Phase 2 Study to Commence Q1 2020 – Data Q4 2020 — Approximately
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Phase 2 Study to Commence Q1 2020 Data Q4 2020 Million in Cash and Cash Equivalents at December AMAG Announced Plans to Divest for Premenopausal Women Sexual Desire Diso
Read more →PTNPalatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020
CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference ca
Read more →PTNPalatin Provides Corporate Update and 2020 Calendar Outlook
CRANBURY, N.J., Jan. 21, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today provide
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update Vyleesi™ launched nationally in September Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update Vyleesi launched nationally in Teleconference and Webcast to be held on November 13, CRANBURY, NJ November 13, 2019 Palatin Technologies, Inc. (NYSE American: PTN), a spec
Read more →PTNPalatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019
CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference c
Read more →PTNPalatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics
CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of Pre-Clinical Development, provided a presentation on Palatin's oral colon delivery formulation, PL8177 in development for the
Read more →PTNVyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data on Vyleesi™ (bremelanotide injection) for hypoac
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results Teleconference and Webcast to be held on September 12, CRANBURY, NJ September 12, 2019 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-
Read more →PTNPalatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019
CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S. financial markets. Palatin will also conduct a c
Read more →PTNPalatin Technologies To Present At Canaccord Genuity
CRANBURY, N.J., Aug. 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that it will be presenting at Canaccord Genuity's 39th Annual Growth Conference on Wednesday, August 7, 2019, at 10:30 am ET. The conference will be held at the InterConti
Read more →PTNPalatin Technologies Provides Mid-Calendar Year Corporate Update
CRANBURY, N.J., July 1, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNFDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
CRANBURY, N.J., June 21, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval of AMAG Pharmaceuticals, Inc.'s New Drug Application (NDA) for Vyleesi™ (bremelanotide inj
Read more →PTNFDA Approves New Drug Application for Vyleesi™ (bremelanotide injection) First FDA-Approved As-Needed Treatment for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women NDA Approva
FDA Approves New Drug Application for Vyleesi (bremelanotide First FDA-Approved As-Needed Treatment for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal NDA Approval Triggers $60 Million Milestone Payment to N.J., June 21, 2019 -- Palatin Techno
Read more →PTNPalatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
CRANBURY, N.J., June 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019 CRANBURY, NJ May 9, 2019 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptid
Read more →PTNPalatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019
CRANBURY, N.J., May 3, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and
Read more →PTNPalatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases
CRANBURY, N.J., April 4, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNBlueprint Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 and Provides Corporate Update Teleconference and Webcast to be held on February 12, CRANBURY, NJ February 12, 2019 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developin
Read more →PTNPalatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update
CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems fo
Read more →PTNPalatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019
CRANBURY, N.J., Feb. 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2019 operating results on Tuesday, February 12, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference ca
Read more →PTNPalatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update Teleconference and Webcast to be held on November 13, CRANBURY, NJ November 13, 2018 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company de
Read more →PTNPalatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist
CRANBURY, N.J., Nov. 8, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNPalatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018
CRANBURY, N.J., Nov. 7, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference cal
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results Vyleesi New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, CRANBURY, NJ September 13, 2018 Palatin Techno
Read more →PTNPalatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018
CRANBURY, N.J., Sept. 7, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018 before the open of the U.S. financial markets. Palatin will also conduct a co
Read more →PTNPalatin Technologies Added to Russell 3000® Index
CRANBURY, N.J., June 25, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNPalatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
CRANBURY, N.J., June 4, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, annou
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018 CRANBURY, NJ May 15, 2018 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific pept
Read more →PTNPalatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018
CRANBURY, N.J., May 10, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call an
Read more →PTNPalatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts
CRANBURY, N.J., May 9, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announ
Read more →PTNPalatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
CRANBURY, N.J., April 3, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, CRANBURY, NJ February 12, 2018 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specifi
Read more →PTNPalatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
CRANBURY, N.J., Feb. 7, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference ca
Read more →PTNPalatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today
Read more →PTNPalatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For Ulcerative Colitis
CRANBURY, N.J., Jan. 3, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNPalatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea
CRANBURY, N.J., Nov. 21, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; "Palatin") announced today that it has entered into a collaboration and license agreement with Kwangdong Pharmaceutical Co., Ltd. ("Kwangdong"), for exclusive rights to develop and commercial
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, CRANBURY, NJ November 13, 2017 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific pept
Read more →PTNPalatin Technologies, Inc. to Report First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017
CRANBURY, N.J., Nov. 8, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2018 operating results on Monday, November 13, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conference call and
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, CRANBURY, NJ September 25, 2017 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specif
Read more →PTNPalatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017
CRANBURY, N.J., Sept. 20, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter and fiscal year end 2017 operating results on Monday, September 25, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conferen
Read more →PTNPalatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors CRANBURY, N.J.
Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to N.J., September 12, 2017 -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with signi
Read more →PTNPalatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories CRANBURY, NJ –
Palatin Technologies Announces Signing of Licensing Agreement with Rights to Bremelanotide in China and Other Selected NJ September 6, 2017 Palatin Technologies, Inc. (NYSE MKT: PTN; Palatin ) announced today that it has entered into a collaboration and license agreement with
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017 CRANBURY, NJ May 16, 2017 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide t
Read more →PTNPalatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
CRANBURY, N.J., May 11, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2017 operating results on Tuesday, May 16, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conference call and liv
Read more →PTNPalatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
CRANBURY, N.J., March 20, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies To Present At The 29th Annual ROTH Conference
CRANBURY, N.J., March 9, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 a.m. Pacific Time. The conference will be held at The Ritz Carlton Laguna Ni
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, NJ February 9, 2017 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therape
Read more →PTNPalatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™ Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Pr
Technologies Announces Closing of License Agreement AMAG Pharmaceuticals for North American Rights to Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs Teleconference and Webcast to be held on February 9, February 3, 2017 Palatin
Read more →PTNPalatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the closing of its licensing agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelano
Read more →PTN(Monday, January 9 @ 8 a.m.) AMAG PHARMACEUTICALS AND PALATIN TECHNOLOGIES ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NORTH AMERICAN RIGHTS TO REKYNDA TM (BREMELANOTIDE), A POTENTIAL TREATMENT FOR
(Monday, January 9 @ 8 AMAG PHARMACEUTICALS AND PALATIN TECHNOLOGIES ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NORTH AMERICAN RIGHTS TO REKYNDATM (BREMELANOTIDE), A POTENTIAL TREATMENT FOR A COMMON FEMALE SEXUAL DISORDER Two Phase 3 trials completed for Rekynda; co-prima
Read more →PTNPalatin Technologies Closes on $16.5 Million Financing
CRANBURY, N.J., Dec. 7, 2016 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE MKT: PTN) announced that it has closed on a previously disclosed underwritten public offering of units with gross proceeds of $16,500,000. Canaccord Genuity acted as sole book-running manage
Read more →PTNPalatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants
CRANBURY, N.J., Dec. 1, 2016 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE MKT: PTN) today announced the pricing of an underwritten public offering of 25,384,616 shares of its common stock and warrants to purchase 12,692,310 shares of its common stock for anticipat
Read more →PTNPalatin Technologies Announces Proposed Public Offering of Common Stock and Warrants CRANBURY, NJ
Technologies Announces Proposed Public Offering of Common Stock and November 30, 2016 (PRNewswire) -- Palatin Technologies, Inc. ( Palatin ) (NYSE MKT: PTN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue
Read more →PTNPalatin Technologies Announces Proposed Public Offering of Common Stock and Warrants
CRANBURY, N.J., Nov. 30, 2016 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE MKT: PTN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and warrants to purchas
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on November 15, CRANBURY, NJ November 15, 2016 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific pept
Read more →PTNPalatin Technologies, Inc. to Report First Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on November 15, 2016
CRANBURY, N.J., Nov. 10, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2017 operating results on Tuesday, November 15, 2016 before the open of the U.S. financial markets. Palatin will also conduct a conference call a
Read more →PTNBremelanotide Meets Co-Primary Endpoints in
For Immediate Release November 1, 2016 Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Both Phase 3 Reconnect Studies of bremelanotide for hypoactive sexual desire disorder (HSDD) in premenopausal women met the pre-specified
Read more →PTNPalatin Technologies Receives Audit Opinion with Going Concern Explanation
CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today ann
Read more →PTNPalatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results CRANBURY, NJ –
Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results CRANBURY, NJ September 20, 2016 Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases wi
Read more →PTNPalatin Technologies, Inc. to Report Fourth Quarter Fiscal Year End 2016 Results; Teleconference and Webcast to be held on September 20, 2016
CRANBURY, N.J., Sept. 14, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2016 operating results on Tuesday, September 20, 2016 before the open of the U.S. financial markets. Palatin will also conduct a conference
Read more →PTNPalatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference
CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced t
Read more →PTNPalatin Technologies Announces Closing of $9.2 Million Financing
CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced t
Read more →PTNPalatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient visits in the Company's reconnect studies, consisting of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexua
Read more →PTNPalatin Technologies Announces $9.25 Million Financing
CRANBURY, N.J., Aug. 1, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has priced an underwritten offering of units with anticipated gross proceeds of $9.25 million. Each unit will consist of a share of common stock and a Series H warrant
Read more →PTNPalatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property
CRANBURY, N.J., June 6, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced t
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on May 17, 2016
CRANBURY, N.J., May 17, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNFor Release
For Release May 17, 2016 at 7:30 a.m. ET Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on May 17, 2016 CRANBURY, NJ - May 17, 2016 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company deve
Read more →PTNPalatin Technologies, Inc. to Report Third Quarter Fiscal Year 2016 Results
CRANBURY, N.J., May 12, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2016 operating results on Tuesday, May 17, 2016 before the open of the U.S. financial markets. Palatin will also conduct a conference call and liv
Read more →PTNPalatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women
CRANBURY, N.J., Feb. 26, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016 CRANBURY, NJ - February 16, 2016 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-speci
Read more →PTNPalatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results
CRANBURY, N.J., Feb. 10, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2016 operating results on Tuesday, February 16, 2016 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
CRANBURY, N.J., Feb. 8, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced t
Read more →PTNPalatin Technologies To Present At The BIO CEO & Investor Conference
CRANBURY, N.J., Feb. 4, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 18th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference wi
Read more →PTNPalatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
Palatin Technologies Reconnect Study Logo CRANBURY, N.J., Dec. 10, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medica
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015 CRANBURY, NJ - November 12, 2015 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specif
Read more →PTNPalatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015
CRANBURY, N.J., Nov. 10, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2016 operating results on Thursday, November 12, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPreclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting
CRANBURY, N.J., Sept. 28, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today ann
Read more →PTNPalatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction
CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today ann
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results CRANBURY, NJ
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results CRANBURY, NJ - September 21, 2015 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseas
Read more →PTNPalatin Technologies, Inc. To Report Fourth Quarter Fiscal Year End 2015 Results
CRANBURY, N.J., Sept. 16, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2015 operating results on Monday, September 21, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference
Read more →PTNPalatin Technologies Supports FDA
CRANBURY, N.J., Aug. 18, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin
Read more →PTNFOR RELEASE
FOR RELEASE July 6, 2015 at 7:30 a.m. ET Palatin Technologies Completes $30 Million Financing $20 Million Equity and $10 Million Debt CRANBURY, NJ and FARMINGTON, CT - July 6, 2015 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, r
Read more →PTNPalatin Technologies Completes $30 Million Financing
CRANBURY, N.J. and FARMINGTON, Conn., July 6, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial
Read more →PTNPalatin Supports FDA Advisory Committee
CRANBURY, N.J., June 4, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) - Today's FDA Advisory Committee's recommendation for the approval of flibanserin is an important step forward in women's health, as the decision addresses the important need for the women li
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on May 13, 2015
CRANBURY, N.J., May 13, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNPalatin Technologies, Inc. To Report Third Quarter Fiscal Year 2015 Results
CRANBURY, N.J., May 8, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2015 operating results on Wednesday, May 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and li
Read more →PTNPalatin Technologies To Present At The 27th Annual ROTH Conference
CRANBURY, N.J., March 6, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 27th Annual ROTH Conference on Wednesday, March 11, 2015, at 10:30 a.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna
Read more →PTNPalatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual Dysfunction
CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today ann
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015
CRANBURY, N.J., Feb. 13, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and Webcast to be held on February 13, 2015
CRANBURY, N.J., Feb. 9, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call an
Read more →PTNPalatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today ann
Read more →PTNPalatin Completes $20 Million Equity and $10 Million Debt Financings CRANBURY, NJ and FARMINGTON, CT
Palatin Completes $20 Million Equity and $10 Million Debt Financings CRANBURY, NJ and FARMINGTON, CT - December 24, 2014 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of dis
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014
CRANBURY, N.J., Nov. 18, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies, Inc. To Report First Quarter Fiscal Year 2015 Results
CRANBURY, N.J., Nov. 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2015 operating results on Tuesday, November 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call a
Read more →PTNSurvey Reveals Low Sexual Desire Disrupts Relationships
RED BANK, N.J., Nov. 4, 2014 /PRNewswire/ -- Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire
Read more →PTNPalatin Technologies To Present At The 13th Annual BIO Investor Forum
CRANBURY, N.J., Oct. 8, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting today at the 13th Annual BIO Investor Forum at 11:00 a.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Invest
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results
CRANBURY, N.J., Sept. 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2014 Results
CRANBURY, N.J., Sept. 4, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2014 operating results on Tuesday, September 9, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter
CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement to co-develop and co
Read more →PTNPalatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
CRANBURY, N.J., July 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced t
Read more →PTNPalatin Technologies to Join Russell Microcap Index
CRANBURY, N.J., June 27, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides
CRANBURY, N.J., June 10, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNNew Survey Reveals That Low Sexual Desire Disrupts Relationships
RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on May 13, 2014
CRANBURY, N.J., May 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNPalatin Technologies, Inc. To Report Third Quarter Fiscal Year 2014 Results
CRANBURY, N.J., May 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2014 operating results on Tuesday, May 13, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live
Read more →PTNPalatin Technologies Presents at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG)
CRANBURY, N.J., April 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presente
Read more →PTNPalatin Technologies Announces Option Extension for License to Bremelanotide in Europe
CRANBURY, N.J., March 31, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies To Present At The 26Th Annual ROTH Conference
CRANBURY, N.J., March 6, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
CRANBURY, N.J., Feb. 18, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
CRANBURY, N.J., Feb. 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine
CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be prese
Read more →PTNPalatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits
CRANBURY, N.J., Jan. 23, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies Responds to Unusual Market Activity
CRANBURY, N.J., Jan. 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) (the "Company") announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange") has contacted the Company
Read more →PTNPalatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference
CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on Dece
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies Announces Option for License to Bremelanotide in Europe
CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced
Read more →PTNPalatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
CRANBURY, N.J., Nov. 11, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2014 operating results on Thursday, November 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe
Read more →PTNPalatin Technologies to Present at the 12th Annual BIO Investor Forum
CRANBURY, N.J., Oct. 4, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 3:30 p.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 1
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
CRANBURY, N.J., Sept. 25, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2013 operating results on Monday, September 30, 2013 after the close of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live
Read more →PTNPalatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced to
Read more →PTNPalatin Technologies To Present At The 25th Annual ROTH Conference
CRANBURY, N.J., March 15, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 25th Annual ROTH Conference on Monday, March 18, 2013, at 1:00 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in
Read more →PTNFor U.S. Media Palatin Technologies Presents Positive Data for Bremelanotide in Female Sexual Dysfunction Data from first-in-class investigational treatment presented at the International Society for the St
Palatin Technologies, Palatin Technologies Presents Positive Bremelanotide in Female Sexual Dysfunction from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in New Orleans NJ - March 1
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference wi
Read more →PTNPalatin Technologies Receives $1.75 Million from Sale Of New Jersey State Tax Credits
CRANBURY, N.J., Jan. 3, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today it has received net proceeds of approximately $1.75 million of non-dilutive funding through the New Jersey Economic Development Authority's tax credit transfer program. Palatin
Read more →PTNPalatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
CRANBURY, N.J., Nov. 20, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 3:10 p.m. Eastern Time. The conference will be held at The New Yor
Read more →PTNPalatin Technologies November 2012 Carl Spana, Ph.D. President & CEO Stephen T. Wills, CPA/MST CFO / COO The statements in this presentation that relate to future plans, events or performance are forward - looking statem
Palatin Technologies 8-K Palatin Technologies November 2012 Carl Spana, Ph.D. President & CEO Stephen T. Wills, CPA/MST CFO / COO The statements in this presentation that relate to future plans, events or performance are forward - looking statements, which are made pursuant to
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on
Palatin Technologies, Inc. 8-K Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012 November 14, 2012 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted,
Read more →PTNPalatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time. The conference will be held at T
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial e
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results CRANBURY, NJ
Palatin Technologies, Inc. 8-K Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results CRANBURY, NJ - September 11, 2012 - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeu
Read more →PTNPalatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (F
Read more →PTNPalatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of develop
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
CRANBURY, N.J., Sept. 6, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2012 financial results on Tuesday, September 11, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNFOR RELEASE JULY 2, 2012 at 4:30 p.m. ET Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants CRANBURY, NJ
PALATIN TECHNOLOGIES, INC. 8-K RELEASE JULY 2, 2012 at 4:30 p.m. ET Technologies, Inc. Announces Pricing of Million Private Placement of Common Stock and Warrants NJ - July 2, 2012 - Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a defini
Read more →PTNPalatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
CRANBURY, N.J., July 2, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shar
Read more →PTNPalatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for th
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
CRANBURY, N.J., May 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today annou
Read more →PTNPalatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
CRANBURY, N.J., May 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2012 financial results on Monday, May 14, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live
Read more →PTNPalatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial
CRANBURY, N.J., March 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). Over 400 prem
Read more →PTNPalatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
CRANBURY, N.J., March 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 24th Annual ROTH OC Growth Stock Conference on Tuesday, March 13, 2012, at 1:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be Held on February 15, 2012
CRANBURY, N.J., Feb. 15, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today anno
Read more →PTNPalatin Technologies to Present at 14th Annual BIO CEO & Investor Conference
CRANBURY, N.J., Feb. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 8:30 a.m. ET. Hosted by the Biotechnology Industry Organization (BIO), th
Read more →PTNPalatin Technologies, Inc. to Report Fiscal Year 2012 Second Quarter Results; Teleconference and Webcast to be Held on February 15, 2012
CRANBURY, N.J., Feb. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its second quarter, fiscal year 2012 financial results on Wednesday, February 15, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference cal
Read more →PTNPalatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits
CRANBURY, N.J., Jan. 17, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today it has received net proceeds of approximately $1.1 million of non-dilutive funding through the New Jersey Economic Development Authority's tax credit transfer program. Palati
Read more →PTNPalatin Technologies to Present at BOCEMb, Noble Financial Capital Markets
CRANBURY, N.J., Jan. 16, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today ann
Read more →PTNPalatin Technologies to Present at Windhover
CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today ann
Read more →PTNPalatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
CRANBURY, N.J., Nov. 10, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2012 financial results on Tuesday, November 15, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter a
Read more →PTNPalatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference c
Read more →PTNPalatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
CRANBURY, N.J., Sept. 9, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 12:05 p.m. Eastern Time. The conference will be held at Th
Read more →PTNPalatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent thera
Read more →PTNAlan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc.
CRANBURY, N.J., June 23, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that Alan W. Dunton, M.D., formally joined Palatin's Board of Directors on June 22, 2011 as an independent director and member of Palatin's Audit and Compensation Committees.
Read more →PTNPalatin Technologies, Inc. Issued U.S. Patent for Key Component in PL-3994 Drug Candidate
CRANBURY, N.J., June 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs." The claims in the issued patent cover a se
Read more →PTNPalatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexu
Read more →PTNPALATIN TECHNOLOGIES, INC. and Subsidiary Consolidated Balance Sheets (unaudited)
PALATIN TECHNOLOGIES, INC. Consolidated Balance Sheets May 26, 2011 March 31, 2011 ASSETS Current assets: Cash and cash equivalents $ 20,237,231 $ 22,032,649 Prepaid expenses and other current assets 499,970 539,361 Total current assets 20,737,201 22,572,010 Pr
Read more →PTNPRESS RELEASE ex99.htm
FOR RELEASE May 16, 2011 at 7:30 a.m. ET Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results CRANBURY, NJ - May 16, 2011 - Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
CRANBURY, N.J., May 16, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ende
Read more →PTNPalatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011
CRANBURY, N.J., May 12, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming sta
Read more →PTNPalatin Technologies, Inc. Announces Results of Annual Stockholders
CRANBURY, N.J., May 11, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, held its annual meeting of stockholders today in C
Read more →PTNPalatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
CRANBURY, N.J., March 9, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. Pacific Time. The conference will be held at the Ritz Carlto
Read more →PTNFDA Clears Palatin Technologies
CRANBURY, N.J., March 3, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Food and Drug Administration (FDA) has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug (IND) applic
Read more →PTNPalatin Technologies, Inc. Closes $23 Million Public Offering
CRANBURY, N.J., March 1, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it has completed its previously announced public offering of 23,000,000 units, consisting of 23,000,000 shares of its common stock, Series A Warrants to purchase 2,000,0
Read more →PTNPalatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
CRANBURY, N.J., Feb. 24, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the pricing of its underwritten public offering of 23,000,000 units, consisting of 23,000,000 shares of its common stock, Series A Warrants to purchase 2,000,000 shares of it
Read more →PTNPalatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants CRANBURY, NJ
Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants CRANBURY, NJ - February 24, 2011 - Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the pricing of its underwritten public offering of 23,000,000 units, consisting of 23,000,
Read more →PTNPalatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
CRANBURY, N.J., Feb. 23, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it intends to offer and sell units consisting of shares of its common stock and warrants to purchase common stock in an underwritten public offering. The offering is sub
Read more →PTNPalatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
CRANBURY, N.J., Feb. 18, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on February 24, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended December 31, 2010 financial results and plans for its programs under deve
Read more →PTNPalatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
CRANBURY, N.J., Feb. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today
Read more →PTNDATED FEBRUARY 4, 2011 ex99.htm FOR RELEASE FEBRUARY 4, 2011 at 4:05 p.m. ET Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex CRANBURY, NJ
FOR RELEASE FEBRUARY 4, 2011 at 4:05 p.m. ET Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex CRANBURY, NJ - February 4, 2011 - Palatin Technologies, Inc. (NYSE Amex: PTN) reported that its exchange listing compliance plan has been accepted by the NYSE Amex. P
Read more →PTNPalatin Technologies Listing Compliance Plan Accepted by NYSE Amex
CRANBURY, N.J., Feb. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) reported that its exchange listing compliance plan has been accepted by the NYSE Amex. Palatin has been granted an extension until May 26, 2011 to regain compliance with stockholders' equity
Read more →PTNFOR RELEASE DECEMBER 2, 2010 at 4:00 p.m. ET Palatin Technologies Receives Non-Compliance Letter from NYSE Amex Company Expects Its Common Stock to Remain Listed While It Engages in Compliance Process CRANBURY, NJ
FOR RELEASE DECEMBER 2, 2010 at 4:00 p.m. ET Palatin Technologies Receives Non-Compliance Letter from NYSE Amex Company Expects Its Common Stock to Remain Listed While It Engages in Compliance Process CRANBURY, NJ - December 2, 2010 - Palatin Technologies, Inc. (NYSE Amex: PT
Read more →PTNPalatin Technologies Receives Non-Compliance Letter from NYSE Amex
CRANBURY, N.J., Dec. 2, 2010 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today reported it received notice from NYSE Amex LLC (the "Exchange"), advising Palatin that it is not in compliance with certain conditions of the Exchange's continued listing standards unde
Read more →PTNPalatin Technologies Appoints Jeffrey D. Edelson, M.D., Chief Medical Officer
CRANBURY, N.J., Nov. 16, 2010 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the appointment of Jeffrey D. Edelson, M.D., as Chief Medical Officer. Dr. Edelson has more than 15 years of leadership experience in the successful clinical develo
Read more →PTNPalatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
CRANBURY, N.J., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor syst
Read more →PTNPalatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
CRANBURY, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2011 financial results on Tuesday, November 16, 2010 before the open of the U.S. financial markets. Palatin will also conduct a confer
Read more →PTNPalatin Technologies, Inc. Receives $978,000 in Grants Under the Patient Protection and Affordable Care Program
CRANBURY, N.J., Nov. 2, 2010 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no la
Read more →PTNPalatin Technologies to Present at 9th Annual BIO Investor Forum
CRANBURY, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 9th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 8:00 AM PT. Hosted by the Biotechnology Industry Organization (BIO), the 9th Ann
Read more →PTNPalatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2010 Results Teleconference and Webcast to be held on September 27, 2010
CRANBURY, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor
Read more →PTNPalatin Announces Strategic Realignment of Operations
CRANBURY, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the realignment of its workforce and operations to reflect a strategic reassessment of its research and development activities and corporate objectives. As a result, Pal
Read more →PTNPalatin Technologies, Inc. to Report Fiscal Year 2010 Fourth Quarter Results; Teleconference and Webcast to be held on September 27, 2010
CRANBURY, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2010 financial results on Monday, September 27, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference
Read more →PTNPRESENTATION ON SEPTEMBER 14, 2010
PRESENTATION ON SEPTEMBER 14, 2010
Read more →PTNPalatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
CRANBURY, N.J., Sept. 10 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference / 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 10:50 AM ET. The conference
Read more →PTNPalatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
CRANBURY, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunct
Read more →PTNPRESS RELEASE ex99-1.htm
FOR IMMEDIATE RELEASE June 25, 2010 Palatin Technologies, Inc. To Raise $2.0 Million Dollars In Registered Direct Offering CRANBURY, NJ - June 25, 2010 - Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered into definitive agreements with certain acc
Read more →PTNPalatin Technologies, Inc. Reports Third Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on
Technologies, Inc. Reports Third Quarter Fiscal Year 2010 Teleconference and Webcast to be held on May 13, 2010 NJ - May 13, 2010 - Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small
Read more →PTNPalatin Technologies, Inc. To Raise $2.6 Million Dollars In Registered Direct Offering CRANBURY, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered int
Technologies, Inc. To Raise $2.6 Million Dollars In Registered Direct N.J., Feb. 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered into definitive agreements with certain accredited investors to sell in a registered di
Read more →PTNFOR RELEASE SEPTEMBER 29, 2009 at 7:30 a.m. ET Palatin Technologies to Receive $5 Million from AstraZeneca CRANBURY, NJ
FOR RELEASE SEPTEMBER 29, 2009 at 7:30 a.m. ET Palatin Technologies to Receive $5 Million from AstraZeneca CRANBURY, NJ September 29, 2009 Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it will receive $5 million from AstraZeneca relating to an amendment o
Read more →PTNPALATIN TECHNOLOGIES, INC. TO RAISE $3.1
PALATIN TECHNOLOGIES, INC. TO RAISE $3.1 MILLION IN REGISTERED DIRECT OFFERING CRANBURY, NJ August 12, 2009 Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it will raise approximately $3.1 million in gross proceeds, before deducting placement agent fees and
Read more →PTNFOR RELEASE MARCH 5, 2009 at 7:30 a.m. ET Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext
FOR RELEASE MARCH 5, 2009 at 7:30 a.m. ET Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US CRANBURY, NJ March 5, 2009 Palatin Technologies, Inc. (NYSE Alternext US: PTN) reported that its exchange listing compliance plan submitted on January 23, 2
Read more →PTNFOR RELEASE FEBRUARY 17, 2009 at 7:30 a.m. ET Palatin Technologies, Inc. Reports Fiscal Year 2009 Second Quarter Results; Teleconference and Webcast to be held on
FOR RELEASE FEBRUARY 17, 2009 at 7:30 a.m. ET Technologies, Inc. Reports Fiscal Year 2009 Second Quarter Results; Webcast to be held on February 17, 2009 CRANBURY, NJ February 17, 2009 Palatin Technologies, Inc. (NYSE Alternext US: PTN) announced today results for its secon
Read more →PTNPress Release dated
FOR RELEASE DECEMBER 30, Palatin Technologies Receives Notification Letter from NYSE Alternext US Common Stock to Remain Listed While it Engages in Compliance Cranbury, NJ December 30, 2008 Palatin Technologies, Inc. (NYSE Alternext US: PTN) today reported it received noti
Read more →PTNFOR RELEASE SEPTEMBER 30, 2008 at 7:30 a.m. ET Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on
FOR RELEASE SEPTEMBER 30, 2008 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on CRANBURY, NJ September 30, 2008 Palatin Technologies, Inc. (AMEX: PTN) announced today results for its fourth quarter
Read more →PTNFOR RELEASE JULY 1, 2008 at 7:30 a.m. ET Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration CRANBURY, NJ
FOR RELEASE JULY 1, 2008 Palatin Technologies Expanding AstraZeneca Obesity Collaboration CRANBURY, NJ July 1, 2008 Palatin Technologies, Inc. (AMEX: PTN) today announced that AstraZeneca and Palatin have amended their exclusive global licensing and research collaboration a
Read more →PTNFOR RELEASE MAY 13, 2008 at 7:30 a.m. ET Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results CRANBURY, N.J.
2008 at 7:30 a.m. ET Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results CRANBURY, N.J., May 13, 2008 Palatin Technologies, Inc. (Amex: PTN) today reported its financial results for the third quarter ended March 31, 2008
Read more →PTNDATED JANUARY 22, 2008 FOR RELEASE JANUARY 22, 2008 at 7:30 a.m. ET Palatin Technologies Announces Litigation Settlement With Competitive Technologies CRANBURY, NJ
FOR RELEASE JANUARY 22, 2008 at 7:30 a.m. ET Palatin Technologies Announces Litigation Settlement With Competitive Technologies CRANBURY, NJ January 22, 2008 Palatin Technologies, Inc. (AMEX: PTN) announced today that it entered into an agreement to settle all outstanding
Read more →PTNFOR RELEASE NOVEMBER 9, 2007 at 7:30 a.m. ET Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be held on
FOR RELEASE NOVEMBER 9, 2007 at 7:30 Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be held on November 9, 2007 CRANBURY, NJ November 9, 2007 Palatin Technologies, Inc. (AMEX: PTN) announced today financial results fo
Read more →PTNPalatin Technologies, Inc. press release dated
FOR RELEASE SEPTEMBER 26, 2007 at 7:30 a.m. EDT Palatin Technologies Announces Reduction of Workforce CRANBURY, N.J., September 26, 2007 Palatin Technologies, Inc. (AMEX: PTN) (the Company) today announced it has taken steps to reduce its workforce by 30%, resulting in annu
Read more →PTNDATED AUGUST 30, 2007 N E W S R E L E A S E
FOR RELEASE August 30, KING PHARMACEUTICALS AND PALATIN TECHNOLOGIES DELAY IMMEDIATE PLANS FOR PHASE 3 CLINICAL PROGRAM WITH BREMELANOTIDE FOR ERECTILE DYSFUNCTION CRANBURY, N.J. and BRISTOL, Tenn., August 30, 2007 Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuti
Read more →PTNCORPORATE PRESENTATION Corporate Presentation
CORPORATE PRESENTATION Corporate Presentation CORPORATE PRESENTATION
Read more →PTNDATED SEPTEMBER 13, 2006 Palatin Technologies, Inc. press release dated
FOR RELEASE September 13, 2006 at Contacts: For Palatin Technologies: For Institutional Investors and Media: Stephen T. Wills, CPA, MST Carney Duntsch EVP-Operations / Chief Financial Officer Burns McClellan (609) 495-2200 (212) 213-0006 info@palatin.com cduntsch@burnsmc.com T
Read more →PTNDATED MAY 9, 2006 Palatin Technologies, Inc. press release dated
FOR RELEASE MAY 9, 2006 at Contacts: For Palatin Technologies: For Institutional Investors and Media: Stephen T. Wills, CPA, MST Carney Duntsch EVP-Operations / Chief Financial Officer Burns McClellan (609) 495-2200 (212) 213-0006 info@palatin.com cduntsch@burnsmc.com John Bal
Read more →PTNDATED APRIL 17, 2006 Palatin Technologies, Inc. press release dated
Contacts: For Palatin Technologies: For Institutional Investors and Media: Stephen T. Wills, CPA, MST Carney Duntsch EVP-Operations / Chief Financial Officer Burns McClellan (609) 495-2200 (212) 213-0006 info@palatin.com cduntsch@burnsmc.com Palatin Technologies, Inc. Complete
Read more →PTNDATED APRIL 12, 2006 Palatin Technologies, Inc. press release dated
FOR RELEASE APRIL 12, 2006 AT 7:30 a.m. EDT Contacts: For Palatin Technologies: For Institutional Investors and Media: Stephen T. Wills, CPA, MST Carney Duntsch EVP-Operations / Chief Financial Officer Burns McClellan (609) 495-2200 (212) 213-0006 info@palatin.com cduntsch@burn
Read more →PTNPalatin Technologies, Inc. press release dated Semptember 20, 2005 FOR RELEASE Semptember 20, 2005 at 7:30 a.m. EDT Contacts: Palatin Technologies: Burns McClellan: Stephen T. Wills, CPA, MST Carney Duntsch (Media) EVP-O
FOR RELEASE Semptember 20, 2005 at 7:30 a.m. Contacts: Palatin Technologies: Burns McClellan: Stephen T. Wills, CPA, MST Carney Duntsch (Media) EVP-Operations, Chief Financial Officer (212) 213-0006 (609) 495-2200 cduntsch@burnsmc.com info@palatin.com Laura Siino (Investors)
Read more →Competitive Position
How PTN ranks across every disease it competes inCompetitive Position is a premium feature
See how PTN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial